> Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch of a new study
Tag: FullYear
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
– COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio
Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights
Cash position of €62 million at year-end provides runway until the end of H2 2022 Enrolment of SENS-401 Phase 2 SSNHL clinical study progressing Expanding
DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments
Montrouge, France, March 11, 2021 DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 –
22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020
Key Business and Financial Highlights 22nd Century has a tremendous global commercial opportunity in the more than $800 billion markets across the tobacco and hemp/cannabis
Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights
− Enrollment Completed in Phase 3 INVIGORATE Trial, with Top-Line Results Expected in the First Half of 2021 − Top-Line Results from Phase 3 TRANQUILITY
Spero Therapeutics to Present Company Update and Report Fourth Quarter and Full-Year 2020 Monetary Success on Thursday, March 11, 2021
CAMBRIDGE, Mass., March 03, 2021 (World NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical corporation centered on identifying, building and commercializing therapies
Target Corporation Reports Fourth Quarter and Full-Year 2020 Earnings
MINNEAPOLIS, March 2, 2021 /PRNewswire/ — Q4 2020 Highlights Comparable sales grew 20.5 percent, reflecting comparable traffic growth of 6.5 percent and a 13.1 percent